"Trastuzumab therapy" trang 1 - tải miễn phí từ tailieuXANH
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
7    50    0
Quantitative measurements of HER2 and phospho-HER2 expression: Correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab

Quantitative measurements of HER2 and phospho-HER2 expression: Correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
8    63    0
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
7    69    0
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
9    62    0
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: A retrospective single-center study
7    176    2
Báo cáo y học:

Báo cáo y học: "XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer"
6    52    0
báo cáo khoa học:

báo cáo khoa học: "Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report"
4    38    0
Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy
8    75    0
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
10    59    0
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis
15    53    0
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review
8    75    0
Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review
8    98    0
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
14    48    0
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
11    57    0
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients
12    68    0
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
12    67    0
Clinical characteristics and disease outcomes in ER+ breast cancer: A comparison between HER2+ patients treated with trastuzumab and HER2- patients

Clinical characteristics and disease outcomes in ER+ breast cancer: A comparison between HER2+ patients treated with trastuzumab and HER2- patients
10    146    1
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies— the role of HAS2, SHB and HBEGF

Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies— the role of HAS2, SHB and HBEGF
17    17    1
The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: A phase II, multicenter, single-arm study (SYSUCC-005)

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: A phase II, multicenter, single-arm study (SYSUCC-005)
8    13    1
Trastuzumab use in older patients with HER2-positive metastatic breast cancer: Outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)

Trastuzumab use in older patients with HER2-positive metastatic breast cancer: Outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
10    59    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.